Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter …
Post
-
-
Airway Therapeutics secures $50m for Phase IIb/III zelpultide alfa trial
Airway Therapeutics has raised $50m in new equity financing to support its ongoing Phase IIb/III clinical trial of zelpultide alfa …
-
Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex
Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex (CX-5461) as a monotherapy for people with …
-
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data
Bausch + Lomb has chosen to advance two of its pharmaceutical assets further down the clinical pipeline, despite one of …
-
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
In addition to cancer risk factors such as ageing, environmental risk factors, and lifestyle risk factors, family history of cancer …
-
Asia’s clinical research revolution: Why the world’s innovation centre is shifting east
The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials, …
-
Liminatus Pharma selects Synex to advance CAR-T trial
Liminatus Pharma has engaged Korean contract research organisation Synex Consulting to provide clinical research services for the Phase I/IIa study …
-
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
REGENXBIO has reported that the US Food and Drug Administration (FDA) has placed a clinical hold on its investigational gene …
-
Reaching maturity: A roadmap for Quality Excellence amid regulatory transformation
The regulatory landscape across life sciences has faced unprecedented shifts over the past year. Simultaneous realignments of FDA, EU, and …
-
US Executive Order 14420 and potential implications for diphtheria vaccination
On 31 July, the US Centers for Disease Control and Prevention (CDC) published updated surveillance data for diphtheria. Diphtheria is …
-
Industry and federally backed cancer trials diverge in goals, analysis finds
New analysis has revealed that there are several distinctions between the goals of federal and industry-supported oncology clinical trials, which …
-
Analysts praise intismeran’s landmark Phase III win, look to further data
On 19 August, Moderna and MSD (Merck & Co) made history by netting the first late-stage victory for a cancer …
-
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with …
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new …
-
Chemo-free regimen touts breast cancer win amid targeted therapy shift
A new study has revealed that an all-targeted treatment regimen could hold potential as an effective frontline therapeutic option for …
